MEA Cell Fractionation Market

MEA Cell Fractionation Market Size (2023 to 2028)

The Middle East and Africa Cell Fractionation Market size was valued at USD 0.35 Billion in 2023. It is estimated to be growing at a CAGR of 8.65% and worth USD 0.53 Billion by 2028.

Cell Fractionation is in high demand because of the growing number of cultured cell processes used in diagnostic and research applications. As a result, cell lysis/cell fractionation sector companies will see rapid growth in developing countries. The increased frequency of chronic diseases, scientific technology advancements, and supporting regulation for cell-based research in emerging nations are all contributing factors. In addition, the government's increased funding for research, the expansion of the biotechnology and biopharmaceutical sectors, the rise in illness prevalence, and a growing focus on customized therapy are a few of the driving factors for the Middle East and Africa cell fractionation market growth.

The market is further expected to grow due to increased government funding for research, burgeoning biotechnology and biopharmaceutical businesses, a high prevalence of disorders, and a growing emphasis on customized therapy. Researchers are using disruptive cells to study morphology and organization of organelles to develop new cell therapies and other cell-based treatments. Several government bodies have increased their financing to support cell-based research because of its importance. As a result, a slew of government entities has stepped up to give financial aid in the form of investments and funds. Furthermore, there is a significant increase in infectious diseases in the current condition, which is accelerating the market's growth rate.

High expenditure or expense of cell-based research are a few barriers to the cell fractionation market in this region, and providers of cell-based research or public services should spend a lot of money. A scarcity of skilled workers further constrains the Middle East and Africa market's growth rate. In the Cell Fractionation sector, a lack of experienced professionals is a major stumbling block. Furthermore, new entrant survival acts as a restraint in the Cell Fractionation market in the MEA region. COVID-19 has a significant impact on the cell fractionation market, particularly economics. COVID-19 has an economic influence on the cell fractionation market. Furthermore, the COVID-19 pandemic affects the manufacturing supply chain.

This research report has been segmented and sub-segmented the Middle East and Africa Cell Fractionation Market into the following categories.

By Product:

• Consumables
• Reagents
  • Enzymes
  • Detergent Solutions
• Beads
• Disposables
• Instruments
  • Sonicator
  • Homogenizer

By Cell Type: 

• Microbial
• Mammalian

By End User: 

• Research Laboratories
• Biopharmaceuticals
• Biotechnology Companies

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

In this discipline, the requirement for separating subcellular proteins from growing cells has been an enormous achievement. Furthermore, the growing need for pure cellular fractions has prompted the development of new technologies, which has boosted the cell fractionation market in this region. Due to the continuing expansion of the biotechnology sector, the Middle East and Africa Cell Fractionation market is expected to grow significantly over the projected period and continues to grow during the forecast period.

During the forecast period, the cell fractionation market in the Middle East and Africa is likely to be dominated by Saudi Arabia. This is due to increased government financing for R&D, a greater focus on customized medicine, and the growth of the biopharmaceutical and biotechnology sectors. In addition, improvements are also aiding the development of the market in this region in research infrastructure facilities.

UAE is predicted to have the highest share of the Middle East and Africa Cell Fractionation market, following Saudi Arabia. The industry is expected to be driven by biotech methods being adopted by medicine, agriculture, and bio services companies. Furthermore, an increase in investments in R&D linked to biotechnological processes by various government and corporate companies, as well as academia, is predicted to propel the market considerably.

KEY MARKET PLAYERS:

Companies playing a promising role in the MEA cell fractionation market profiled in the report are Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F. Hoffman-La Roche AG, Merck KGaA, Miltenyi Biotec, QIAGEN N., Qsonica and Thermo Fisher Scientific Inc.